Mental health and HIV/AIDS: the need for an integrated response

Robert H Remien, Michael J Stirratt, Nadia Nguyen, Reuben N Robbins, Andrea N Pala, Claude A Mellins, Robert H Remien, Michael J Stirratt, Nadia Nguyen, Reuben N Robbins, Andrea N Pala, Claude A Mellins

Abstract

: Tremendous biomedical advancements in HIV prevention and treatment have led to aspirational efforts to end the HIV epidemic. However, this goal will not be achieved without addressing the significant mental health and substance use problems among people living with HIV (PLWH) and people vulnerable to acquiring HIV. These problems exacerbate the many social and economic barriers to accessing adequate and sustained healthcare, and are among the most challenging barriers to achieving the end of the HIV epidemic. Rates of mental health problems are higher among both people vulnerable to acquiring HIV and PLWH, compared with the general population. Mental health impairments increase risk for HIV acquisition and for negative health outcomes among PLWH at each step in the HIV care continuum. We have the necessary screening tools and efficacious treatments to treat mental health problems among people living with and at risk for HIV. However, we need to prioritize mental health treatment with appropriate resources to address the current mental health screening and treatment gaps. Integration of mental health screening and care into all HIV testing and treatment settings would not only strengthen HIV prevention and care outcomes, but it would additionally improve global access to mental healthcare.

References

    1. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS 2016; 30:1973–1983.
    1. Bavinton BR, Pinto AN, Phanuphak N, Grinsztejn B, Prestage GP, Zablotska-Manos IB, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV 2018; 5:e438–e447.
    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 2016; 375:830–839.
    1. Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA 2016; 316:171–181.
    1. Joint United Nations Programme on HIV/AIDS, & Joint United Nations Programme on HIV/Aids. (2014). 90-90-90: an ambitious treatment target to help end the AIDS epidemic. Geneva, Switzerland: UNAIDS; 2014.
    1. United Nations General Assembly. Resolution no A/RES/70/266, political declaration on HIV and AIDS: on the fast-track to accelerate the fight against HIV and to end the AIDS epidemic by 2030. New York: United Nations; 2017.
    1. Aidala AA, Wilson MG, Shubert V, Gogolishvili D, Globerman J, Rueda S, et al. Housing status, medical care, and health outcomes among people living with HIV/AIDS: a systematic review. Am J Public Health 2016; 106:e1–e23.
    1. Centers for Disease Control and Prevention (CDC). HIV surveillance report 2014. Atlanta, GA: Division of HIV/AIDS Prevention, at Centers for Disease Control; 2015.
    1. Centers for Disease Control and Prevention (CDC). HIV and AIDS in the United States by geographic distribution. Atlanta, GA: Division of HIV/AIDS Prevention, at Centers for Disease Control; 2015.
    1. Dawson L, Kates J. Henry J. Kaiser Family Foundation, What is at stake in ACA repeal and replace for people with HIV?. San Francisco, CA: 2017.
    1. Feller DJ, Agins BD. Understanding determinants of racial and ethnic disparities in viral load suppression: a data mining approach. J Int Assoc Providers AIDS Care 2017; 16:23–29.
    1. Gupta GR, Parkhurst JO, Ogden JA, Aggleton P, Mahal A. Structural approaches to HIV prevention. Lancet 2008; 372:764–775.
    1. Institute for Health Metrics and Evaluation (IHME). GBD compare data visualization. Seattle, WA: Institute for Health Metrics and Evaluation (IHME); 2017.
    1. Centers for Disease Control and Prevention (CDC). HIV prevention in the United States: new opportunities, new expectations. Atlanta, GA: Division of HIV/AIDS Prevention, at Centers for Disease Control; 2015.
    1. Hobkirk AL, Towe SL, Lion R, Meade CS. Primary and secondary HIV prevention among persons with severe mental illness: recent findings. Curr HIV AIDS Rep 2015; 12:406–412.
    1. Blank MB, Himelhoch SS, Balaji AB, Metzger DS, Dixon LB, Rose CE, et al. A multisite study of the prevalence of HIV with rapid testing in mental health settings. Am J Public Health 2014; 104:2377–2384.
    1. Centers for Disease Control and Prevention (CDC). Prevalence of diagnosed and undiagnosed HIV infection-United States, 2008–2012. Atlanta, GA: Division of HIV/AIDS Prevention, at Centers for Disease Control; 2015.
    1. Himelhoch S, Goldberg R, Calmes C, Medoff D, Slade E, Dixon L, et al. Screening for and prevalence of HIV and hepatitis C among an outpatient urban sample of people with serious mental illness and co-occurring substance abuse. J Community Psychol 2011; 39:231–239.
    1. Acuda SW, Sebit MB. Serostatus surveillance testing of HIV-I infection among Zimbabwean psychiatric inpatients, in Zimbabwe. Cent Afr J Med 1996; 42:254–257.
    1. Collins PY, Berkman A, Mestry K, Pillai A. HIV prevalence among men and women admitted to a South African public psychiatric hospital. AIDS Care 2009; 21:863–867.
    1. Lundberg P, Nakasujja N, Musisi S, Thorson AE, Cantor-Graae E, Allebeck P. HIV prevalence in persons with severe mental illness in Uganda: a cross-sectional hospital-based study. Int J Mental Health Syst 2013; 7:20.
    1. Maling S, Todd J, Van der Paal L, Grosskurth H, Kinyanda E. HIV-1 seroprevalence and risk factors for HIV infection among first-time psychiatric admissions in Uganda. AIDS Care 2011; 23:171–178.
    1. Abayomi O, Adelufosi A, Adebayo P, Ighoroje M, Ajogbon D, Ogunwale A. HIV risk behavior in persons with severe mental disorders in a psychiatric hospital in Ogun, Nigeria. Ann Med Health Sci Res 2013; 3:380–384.
    1. Bonfils KA, Firmin RL, Salyers MP, Wright ER. Sexuality and intimacy among people living with serious mental illnesses: factors contributing to sexual activity. Psychiatr Rehabil J 2015; 38:249–255.
    1. Guimaraes MD, McKinnon K, Cournos F, Machado CJ, Melo AP, Campos LN, et al. Correlates of HIV infection among patients with mental illness in Brazil. AIDS Care 2014; 26:505–513.
    1. Hariri AG, Karadag F, Gokalp P, Essizoglu A. Risky sexual behavior among patients in Turkey with bipolar disorder, schizophrenia, and heroin addiction. J Sex Med 2011; 8:2284–2291.
    1. Meade CS, Sikkema KJ. HIV risk behavior among adults with severe mental illness: a systematic review. Clin Psychol Rev 2005; 25:433–457.
    1. Rosenberg SD, Goodman LA, Osher FC, Swartz MS, Essock SM, Butterfield MI, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health 2001; 91:31–37.
    1. Smith MD. HIV risk in adolescents with severe mental illness: literature review. J Adolesc Health 2001; 29:320–329.
    1. Mimiaga MJ, O’Cleirigh C, Biello KB, Robertson AM, Safren SA, Coates TJ, et al. The effect of psychosocial syndemic production on 4-year HIV incidence and risk behavior in a large cohort of sexually active men who have sex with men. J Acquir Immune Defic Syndr 19992015; 68:329–336.
    1. Mangurian C, Cournos F, Schillinger D, Vittinghoff E, Creasman JM, Lee B, et al. Low rates of HIV testing among adults with severe mental illness receiving care in community mental health settings. Psychiatr Serv 2017; 68:443–448.
    1. Meade CS, Sikkema KJ. Voluntary HIV testing among adults with severe mental illness: frequency and associated factors. AIDS Behav 2005; 9:465–473.
    1. Senn TE, Carey MP. HIV testing among individuals with a severe mental illness: review, suggestions for research, and clinical implications. Psychol Med 2009; 39:355–363.
    1. Defechereux PA, Mehrotra M, Liu AY, McMahan VM, Glidden DV, Mayer KH, et al. Depression and oral FTC/TDF preexposure prophylaxis (PrEP) among men and transgender women who have sex with men (MSM/TGW). AIDS Behav 2016; 20:1478–1488.
    1. Mehrotra ML, Glidden DV, McMahan V, Amico KR, Hosek S, Defechereux P, et al. The effect of depressive symptoms on adherence to daily oral PrEP in men who have sex with men and transgender women: a marginal structural model analysis of the iPrEx OLE study. AIDS Behav 2016; 20:1527–1534.
    1. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001; 58:721–728.
    1. Do AN, Rosenberg ES, Sullivan PS, Beer L, Strine TW, Schulden JD, et al. Excess burden of depression among HIV-infected persons receiving medical care in the United States: data from the medical monitoring project and the behavioral risk factor surveillance system. PLoS One 2014; 9:e92842.
    1. Kendall CE, Wong J, Taljaard M, Glazier RH, Hogg W, Younger J, et al. A cross-sectional, population-based study measuring comorbidity among people living with HIV in Ontario. BMC Public Health 2014; 14:161.
    1. O’Cleirigh C, Magidson JF, Skeer MR, Mayer KH, Safren SA. Prevalence of psychiatric and substance abuse symptomatology among HIV-infected gay and bisexual men in HIV primary care. Psychosomatics 2015; 56:470–478.
    1. Mellins CA, Malee KM. Understanding the mental health of youth living with perinatal HIV infection: lessons learned and current challenges. J Int AIDS Soc 2013; 16:18593.
    1. Ickovics JR, Hamburger ME, Vlahov D, Schoenbaum EE, Schuman P, Boland RJ, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001; 285:1466–1474.
    1. Ingersoll K. The impact of psychiatric symptoms, drug use, and medication regimen on nonadherence to HIV treatment. AIDS Care 2004; 16:199–211.
    1. Center for Behavioral Health Statistics and Quality. 2016 National survey on drug use and health: methodological summary and definitions. Rockville, MD: Ubstance Abuse and Mental Health Services Administration; 2017.
    1. Gaynes BN, Pence BW, Eron JJ, Jr, Miller WC. Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. Psychosom Med 2008; 70:505–511.
    1. Bhatia MS, Munjal S. Prevalence of depression in people living with HIV/AIDS undergoing ART and factors associated with it. J Clin Diagn Res 2014; 8:Wc01–Wc04.
    1. Niu L, Luo D, Liu Y, Silenzio VM, Xiao S. The mental health of people living with HIV in China, 1998–2014: a systematic review. PLoS One 2016; 11:e0153489.
    1. Kinyanda E, Hoskins S, Nakku J, Nawaz S, Patel V. Prevalence and risk factors of major depressive disorder in HIV/AIDS as seen in semi-urban Entebbe district, Uganda. BMC Psychiatry 2011; 11:205.
    1. Jonsson GN, Davies N, Freeman C, Joska J, Prahad S, et al. Management of mental health disorders in HIV-positive patients. Southern African J HIV Med 2013; 4:155–165.
    1. Beckerman NL, Auerbach C. Posttraumatic stress disorder and HIV: a snapshot of co-occurrence. Soc Work Healthc 2010; 49:687–702.
    1. Neigh GN, Rhodes ST, Valdez A, Jovanovic T. PTSD co-morbid with HIV: separate but equal, or two parts of a whole?. Neurobiol Dis 2016; 92 (Pt B):116–123.
    1. Sherr L, Nagra N, Kulubya G, Catalan J, Clucas C, Harding R. HIV infection associated posttraumatic stress disorder and posttraumatic growth – a systematic review. Psychol Health Med 2011; 16:612–629.
    1. Tsao JC, Dobalian A, Moreau C, Dobalian K. Stability of anxiety and depression in a national sample of adults with human immunodeficiency virus. J Nerv Ment Dis 2004; 192:111–118.
    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders 5. Washington, DC: American Psychiatric Association; 2013.
    1. Hartzler B, Dombrowski F, Crane H M, Eron F, Geng E H, Christopher Mathews W, et al. Prevalence and predictors of substance use disorders among HIV care enrollees in the United States. AIDS Behav 2017; 21:1138–1148.
    1. Heaton RK, Clifford DB, Franklin DR, Jr, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75:2087–2096.
    1. Ironson G, Fitch C, Stuetzle R. Depression and survival in a 17-year longitudinal study of people with HIV: moderating effects of race and education. Psychosom Med 2017; 79:749–756.
    1. Tsai AC, Bangsberg DR, Frongillo EA, Hunt PW, Muzoora C, Martin JN, et al. Food insecurity, depression and the modifying role of social support among people living with HIV/AIDS in rural Uganda. Soc Sci Med 19822012; 74:2012–2019.
    1. Curry A, Latkin C, Davey-Rothwell M. Pathways to depression: the impact of neighborhood violent crime on inner-city residents in Baltimore, Maryland, USA. Soc Sci Med 19822008; 67:23–30.
    1. Dowdall N, Ward CL, Lund C. The association between neighbourhood-level deprivation and depression: evidence from the south african national income dynamics study. BMC Psychiatry 2017; 17:395.
    1. Jones-Rounds ML, Evans GW, Braubach M. The interactive effects of housing and neighbourhood quality on psychological well being. J Epidemiol Community Health 2014; 68:171–175.
    1. Fialho R, Pereira M, Rusted J, Whale R. Depression in HIV and HCV co-infected patients: a systematic review and meta-analysis. Psychol Health Med 2017; 22:1089–1104.
    1. Fu X, Lawson MA, Kelley KW, Dantzer R. HIV-1 Tat activates indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures in a p38 mitogen-activated protein kinase-dependent manner. J Neuroinflammation 2011; 8:88.
    1. Bird ST, Bogart LM. Perceived race-based and socioeconomic status(SES)-based discrimination in interactions with healthcare providers. Ethn Dis 2001; 11:554–563.
    1. Bogart LM, Wagner GJ, Galvan FH, Landrine H, Klein DJ, Sticklor LA. Perceived discrimination and mental health symptoms among Black men with HIV. Cult Divers Ethn Minor Psychol 2011; 17:295–302.
    1. Dale SK, Bogart LM, Galvan FH, Wagner GJ, Pantalone DW, Klein DJ. Discrimination and hate crimes in the context of neighborhood poverty and stressors among HIV-positive African-American men who have sex with men. J Commun Health 2016; 41:574–583.
    1. Antelman G, Kaaya S, Wei R, Mbwambo J, Msamanga GI, Fawzi WW, et al. Depressive symptoms increase risk of HIV disease progression and mortality among women in Tanzania. J Acquir Immune Defic Syndr 19992007; 44:470–477.
    1. Bemelmans M, Baert S, Negussie E, Bygrave H, Biot M, Jamet C, et al. Sustaining the future of HIV counselling to reach 90–90–90: a regional country analysis. J Int AIDS Soc 2016; 19:20751.
    1. Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr 19992011; 58:181–187.
    1. Krumme AA, Kaigamba F, Binagwaho A, Murray MB, Rich ML, Franke MF. Depression, adherence and attrition from care in HIV-infected adults receiving antiretroviral therapy. J Epidemiol Community Health 2015; 69:284–289.
    1. Musisi S, Wagner GJ, Ghosh-Dastidar B, Nakasujja N, Dickens A, Okello E. Depression and sexual risk behaviour among clients about to start HIV antiretroviral therapy in Uganda. Int J STD AIDS 2014; 25:130–137.
    1. Remien RH, Exner TM, Morin SF, Ehrhardt AA, Johnson MO, Correale J, et al. Medication adherence and sexual risk behavior among HIV-infected adults: implications for transmission of resistant virus. AIDS Behav 2007; 11:663–675.
    1. Uthman OA, Magidson JF, Safren SA, Nachega JB. Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis. Curr HIV AIDS Rep 2014; 11:291–307.
    1. Mugavero MJ, Lin HY, Willig JH, Westfall AO, Ulett KB, Routman JS, et al. Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis 2009; 48:248–256.
    1. Westergaard RP, Hess T, Astemborski J, Mehta SH, Kirk GD. Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. AIDS 2013; 27:2559–2566.
    1. Meyer JP, Althoff AL, Altice FL. Optimizing care for HIV-infected people who use drugs: evidence-based approaches to overcoming healthcare disparities. Clin Infect Dis 2013; 57:1309–1317.
    1. Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. PLoS Med 2016; 13:e1002183.
    1. Kim SH, Gerver SM, Fidler S, Ward H. Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis. AIDS 2014; 28:1945–1956.
    1. Bucek A, Leu CS, Benson S, Warne P, Abrams EJ, Elkington KS, et al. Psychiatric disorders, antiretroviral medication adherence and viremia in a cohort of perinatally HIV-infected adolescents and young adults. Pediatr Infect Dis J 2018; 37:673–677.
    1. Evans DL, Ten Have TR, Douglas SD, Gettes DR, Morrison M, Chiappini MS, et al. Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. Am J Psychiatry 2002; 159:1752–1759.
    1. Leserman J. Role of depression, stress, and trauma in HIV disease progression. Psychosom Med 2008; 70:539–545.
    1. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006; 27:24–31.
    1. Zunszain PA, Anacker C, Cattaneo A, Carvalho LA, Pariante CM. Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:722–729.
    1. Zunszain PA, Hepgul N, Pariante CM. Inflammation and depression. Curr Top Behav Neurosci 2013; 14:135–151.
    1. Lawson MA, Kelley KW, Dantzer R. Intracerebroventricular administration of HIV-1 Tat induces brain cytokine and indoleamine 2,3-dioxygenase expression: a possible mechanism for AIDS comorbid depression. Brain Behav Immun 2011; 25:1569–1575.
    1. Norcini Pala A, Steca P, Bagrodia R, Helpman L, Colangeli V, Viale P, et al. Subtypes of depressive symptoms and inflammatory biomarkers: an exploratory study on a sample of HIV-positive patients. Brain Behav Immun 2016; 56:105–113.
    1. Planes R, Bahraoui E. HIV-1 Tat protein induces the production of IDO in human monocyte derived-dendritic cells through a direct mechanism: effect on T cells proliferation. PLoS One 2013; 8:e74551.
    1. Hong S, Banks WA. Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications. Brain Behav Immun 2015; 45:1–12.
    1. Kaul M, Lipton SA. Mechanisms of neuroimmunity and neurodegeneration associated with HIV-1 infection and AIDS. J Neuroimmune Pharmacol 2006; 1:138–151.
    1. Boasso A, Hardy AW, Anderson SA, Dolan MJ, Shearer GM. HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation. PLoS One 2008; 3:e2961.
    1. Zunszain PA, Anacker C, Cattaneo A, Choudhury S, Musaelyan K, Myint AM, et al. Interleukin-1beta: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 2012; 37:939–949.
    1. Byakwaga H, Boum Y, 2nd, Huang Y, Muzoora C, Kembabazi A, Weiser SD, et al. The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy. J Infect Dis 2014; 210:383–391.
    1. Byakwaga H, Hunt PW, Laker-Oketta M, Glidden DV, Huang Y, Bwana BM, et al. The Kynurenine pathway of tryptophan catabolism and AIDS-associated kaposi sarcoma in Africa. J Acquir Immune Defic Syndr 19992015; 70:296–303.
    1. Martinez P, Tsai AC, Muzoora C, Kembabazi A, Weiser SD, Huang Y, et al. Reversal of the Kynurenine pathway of tryptophan catabolism may improve depression in ART-treated HIV-infected Ugandans. J Acquir Immune Defic Syndr 19992014; 65:456–462.
    1. Siedner MJ, Kim JH, Nakku RS, Bibangambah P, Hemphill L, Triant VA, et al. Persistent immune activation and carotid atherosclerosis in HIV-infected Ugandans receiving antiretroviral therapy. J Infect Dis 2016; 213:370–378.
    1. Pence BW, Mills JC, Bengtson AM, Gaynes BN, Breger TL, Cook RL, et al. Association of increased chronicity of depression with HIV appointment attendance, treatment failure, and mortality among HIV-infected adults in the United States. JAMA Psychiatry 2018; 75:379–385.
    1. Todd JV, Cole SR, Pence BW, Lesko CR, Bacchetti P, Cohen MH, et al. Effects of antiretroviral therapy and depressive symptoms on all-cause mortality among HIV-infected women. Am J Epidemiol 2017; 185:869–878.
    1. Ali G-C, Ryan G, De Silva MJ. Validated screening tools for common mental disorders in low and middle income countries: a systematic review. PLoS One 2016; 11:e0156939.
    1. Sherr L, Clucas C, Harding R, Sibley E, Catalan J. HIV and depression – a systematic review of interventions. Psychol Health Med 2011; 16:493–527.
    1. Sikkema KJ, Dennis AC, Watt MH, Choi KW, Yemeke TT, Joska JA. Improving mental health among people living with HIV: a review of intervention trials in low- and middle-income countries. Glob Ment Health 2015; 2:1–21.
    1. van Luenen S, Garnefski N, Spinhoven P, Spaan P, Dusseldorp E, Kraaij V. The benefits of psychosocial interventions for mental health in people living with HIV: a systematic review and meta-analysis. AIDS Behav 2018; 22:9–42.
    1. Lofgren SM, Nakasujja N, Boulware DR. Systematic review of interventions for depression for people living with HIV in Africa. AIDS Behav 2018; 22:1–8.
    1. Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 2004; 291:2581–2590.
    1. Pence BW, O’Donnell JK, Gaynes BN. The depression treatment cascade in primary care: a public health perspective. Curr Psychiatry Rep 2012; 14:328–335.
    1. Wainberg ML, Scorza P, Shultz JM, Helpman L, Mootz JJ, Johnson KA, et al. Challenges and opportunities in global mental health: a research-to-practice perspective. Curr Psychiatry Rep 2017; 19:28.
    1. Zuckerbrot RA, Cheung A, Jensen PS, Stein REK, Laraque D. Guidelines for adolescent depression in primary care (GLAD-PC): Part I. Practice preparation, identification, assessment, and initial management. Pediatrics 2018; 141:1–23.
    1. Cholera R, Pence BW, Bengtson AM, Crane HM, Christopoulos K, Cole SR, et al. Mind the gap: gaps in antidepressant treatment, treatment adjustments, and outcomes among patients in routine HIV care in a multisite U.S. Clinical Cohort. PLoS One 2017; 12:e0166435.
    1. Asch SM, Kilbourne AM, Gifford AL, Burnam MA, Turner B, Shapiro MF, et al. Underdiagnosis of depression in HIV: who are we missing?. J Gen Intern Med 2003; 18:450–460.
    1. World Health Organization (WHO). Global health expenditure database. Geneva, Switzerland: WHO; 2014.
    1. World Health Organization (WHO). Mental health atlas 2014. Geneva, Switzerland: WHO; 2015.
    1. Chibanda D. Reducing the treatment gap for mental, neurological and substance use disorders in Africa: lessons from the Friendship Bench in Zimbabwe. Epidemiol Psychiatr Sci 2017; 26:342–347.
    1. Chibanda D. Depression and HIV: integrated care towards 90–90–90. Int Health 2017; 9:77–79.
    1. Singla DR, Kohrt BA, Murray LK, Anand A, Chorpita BF, Patel V. Psychological treatments for the world: lessons from low- and middle-income countries. Ann Rev Clin Psychol 2017; 13:149–181.
    1. McKay MM, Chasse KT, Paikoff R, McKinney LD, Baptiste D, Coleman D, et al. Family-level impact of the CHAMP Family Program: a community collaborative effort to support urban families and reduce youth HIV risk exposure. Fam Process 2004; 43:79–93.
    1. Bhana A, McKay MM, Mellins C, Petersen I, Bell C. Family-based HIV prevention and intervention services for youth living in poverty-affected contexts: the CHAMP model of collaborative, evidence-informed programme development. J Int AIDS Soc 2010; 13 Suppl 2:S8.
    1. Bhana A, Mellins CA, Petersen I, Alicea S, Myeza N, Holst H, et al. The VUKA family program: piloting a family-based psychosocial intervention to promote health and mental health among HIV infected early adolescents in South Africa. AIDS Care 2014; 26:1–11.
    1. Mellins CA, Nestadt D, Bhana A, Petersen I, Abrams EJ, Alicea S, et al. Adapting evidence-based interventions to meet the needs of adolescents growing up with HIV in South Africa: the VUKA case example. Glob Soc Welf 2014; 1:97–110.
    1. Pardo G, Saisaengjan C, Gopalan P, Ananworanich J, Lakhonpon S, Nestadt DF, et al. Cultural adaptation of an evidence-informed psychosocial intervention to address the needs of PHIV+ youth in Thailand. Glob Soc Welf 2017; 4:209–218.
    1. Pettifor A, Stoner M, Pike C, Bekker LG. Adolescent lives matter: preventing HIV in adolescents. Curr Opin HIV AIDS 2018; 13:265–273.
    1. UNAIDS. Global HIV & AIDS statistics – 2018 fact sheet. Geneva, Switzerland: UNAIDS; 2017.
    1. Mellins CA. Promoting mental health in adolescents growing up with HIV. In: International AIDS Conference. Amsterdam, Netherlands; 2018.
    1. World Health Organization (WHO). Task shifting: rational redistribution of task among health workforce teams: global recommendations and guidelines. Geneva, Switzerland: WHO; 2008.
    1. Wagner GJ, Ngo V, Goutam P, Glick P, Musisi S, Akena D. A structured protocol model of depression care versus clinical acumen: a cluster randomized trial of the effects on depression screening, diagnostic evaluation, and treatment uptake in Ugandan HIV clinics. PLoS One 2016; 11:e0153132.
    1. Haaga DA. Introduction to the special section on stepped care models in psychotherapy. J Consult Clin Psychol 2000; 68:547–548.
    1. Abas M, Nyamayaro P, Bere T, Saruchera E, Mothobi N, Simms V, et al. Feasibility and acceptability of a task-shifted intervention to enhance adherence to HIV medication and improve depression in people living with HIV in Zimbabwe, a low income country in sub-Saharan Africa. AIDS Behav 2018; 22:86–101.
    1. Sauer-Zavala S, Gutner CA, Farchione TJ, Boettcher HT, Bullis JR, Barlow DH. Current definitions of ‘Transdiagnostic’ in treatment development: a search for consensus. Behav Ther 2017; 48:128–138.
    1. Pachankis JE, Hatzenbuehler ML, Rendina HJ, Safren SA, Parsons JT. LGB-affirmative cognitive-behavioral therapy for young adult gay and bisexual men: a randomized controlled trial of a transdiagnostic minority stress approach. J Consult Clin Psychol 2015; 83:875–889.
    1. Bolton P, Lee C, Haroz EE, Murray L, Dorsey S, Robinson C, et al. A transdiagnostic community-based mental health treatment for comorbid disorders: development and outcomes of a randomized controlled trial among Burmese refugees in Thailand. PLoS Med 2014; 11:e1001757.
    1. Weiss WM, Murray LK, Zangana GA, Mahmooth Z, Kaysen D, Dorsey S, et al. Community-based mental health treatments for survivors of torture and militant attacks in Southern Iraq: a randomized control trial. BMC Psychiatry 2015; 15:249.
    1. Kempf MC, Huang CH, Savage R, Safren SA. Technology-delivered mental health interventions for people living with HIV/AIDS (PLWHA): a review of recent advances. Curr HIV AIDS Rep 2015; 12:472–480.
    1. Remien RH, Mellins CA, Robbins RN, Kelsey R, Rowe J, Warne P, et al. Masivukeni: development of a multimedia based antiretroviral therapy adherence intervention for counselors and patients in South Africa. AIDS Behav 2013; 17:1979–1991.
    1. Andrews G, Williams AD. Up-scaling clinician assisted internet cognitive behavioural therapy (iCBT) for depression: a model for dissemination into primary care. Clin Psychol Rev 2015; 41:40–48.
    1. Rosso IM, Killgore WD, Olson EA, Webb CA, Fukunaga R, Auerbach RP, et al. Internet-based cognitive behavior therapy for major depressive disorder: a randomized controlled trial. Depress Anxiety 2017; 34:236–245.
    1. Prevention Access Campaign. Risk of sexual transmission of HIV from a person living with HIV who has an undetectable viral load. Messaging Primer and Consensus Statement. 2018.
    1. Eisinger RW, Fauci AS. Ending the HIV/AIDS pandemic. Emerg Infect Dis 2018; 24:413–416.
    1. Golub S. PrEP can ‘Do More’: synergistic effects on primary care, insurance and mental health. Miami, FL: IAPAC; 2015.
    1. Grant RM, Koester KA. What people want from sex and preexposure prophylaxis. Curr Opin HIV AIDS 2016; 11:3–9.
    1. Koester K, Amico R, Liu AY, McMahan V, Hosek S, Mayer KH, et al. Sex on PrEP: qualitative findings from the iPrEx open label extension (OLE) in the US. In: International AIDS Conference. Melbourne, Australia.
    1. Marcus JL, Levine K, Grasso C, Krakower DS, Powell V, Bernstein KT, et al. HIV preexposure prophylaxis as a gateway to primary care. Am J Public Health 2018; 108:1418–1420.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir